Breyer Capital, led by billionaire Jim Breyer, recently announced the appointment of Morgan Cheatham as Partner and Head of Healthcare and Life Sciences. This move signifies the firm’s commitment to advancing breakthroughs in biomedicine and healthcare AI. Cheatham, previously a Vice President at Bessemer Venture Partners, brings a unique perspective to venture capital as a soon-to-be MD from Brown’s Warren Alpert Medical School and a published AI researcher with a focus on Pediatrics-Genetics at Harvard/Boston Children’s Hospital.
Cheatham’s journey to Breyer Capital began a decade ago when he crossed paths with Jim Breyer at Brown University. Inspired by Breyer’s vision of reshaping medicine through computation and investment, Cheatham ventured into venture capital and eventually co-invested with Breyer on projects centered around computational medicine and transformative care models. During his tenure at Bessemer Venture Partners, Cheatham led the firm’s healthcare AI investments, incubated a cardiology business, and spearheaded initiatives like the Deep Health Seed Program.
At Breyer Capital, Cheatham will lead healthcare and life sciences investing, focusing on computational methods and precision medicine. Jim Breyer, known for his successful investments in companies like Facebook, emphasizes the importance of Cheatham’s clinical insight and venture experience in driving transformative science forward. The firm’s portfolio includes a diverse range of companies across AI, healthcare, consumer tech, and enterprise software, reflecting Breyer’s long-term, idea-driven investment strategy.
Breyer Capital’s partnership with research universities like Harvard Medical School underscores their commitment to supporting AI-powered precision medicine and healthcare innovation. The collaboration between Breyer and Cheatham represents a unique blend of generational investing experience and domain expertise, positioning the firm to reimagine the infrastructure of modern care through software-driven platforms.
Looking ahead, Breyer Capital sees the future of medicine as being shaped by code-driven breakthroughs. Jim Breyer and Morgan Cheatham are excited to invest in the next generation of companies that leverage the convergence of discovery, clinical need, and institutional change to drive meaningful advancements in healthcare. As the firm continues to champion bold ideas in biomedicine, their collective vision underscores the transformative potential of code in shaping the future of healthcare delivery.
